Dermadis is developing a biologic to treat dermatology disorders by controlling specific biological pathways.
The company, which got the young innovative status (JEI) is located in a cluster of biotech companies. Dermadis was founded to firstly develop inhibitors of kallikreins in the dermatology field. The recent discoveries of the importance of kallikreins in skin diseases, and the potential of kallikrein inhibitors as therapeutic agents in dermatological disorders are the core business of Dermadis. XXX patients are waiting for efficient treatment.